{"nctId":"NCT00909181","briefTitle":"Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence","startDateStruct":{"date":"2009-03"},"conditions":["Urge Urinary Incontinence","Urinary Frequency"],"count":626,"armGroups":[{"label":"Oxybutynin Gel 56 mg/day","type":"EXPERIMENTAL","interventionNames":["Drug: Oxybutynin","Drug: Placebo"]},{"label":"Oxybutynin Gel 84 mg/day","type":"EXPERIMENTAL","interventionNames":["Drug: Oxybutynin","Drug: Placebo"]},{"label":"Placebo Gel","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Oxybutynin","Drug: Placebo"]}],"interventions":[{"name":"Oxybutynin","otherNames":["Anturol; Oxybutynin Gel 3%"]},{"name":"Placebo","otherNames":["Anturol; Oxybutynin Gel 3%"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Overactive bladder (OAB) symptoms of urge and/or mixed UI with a predominance of urge incontinence for at least 3 months\n* Have a history of at least 1 - 2 urge episodes and 8 or more voids per day\n\nExclusion Criteria:\n\n* Incontinence that is predominantly stress, insensate, or overflow in nature, or incontinence related to chronic illness, anatomical weakness/abnormalities or concomitant medications\n* PVR volume \\> 200 mL or relative PVR \\> 50% of pre-void volume as determined by bladder ultrasound\n* History of urinary retention, gastric retention, or uncontrollable narrow-angle glaucoma, or patients who are at risk for these conditions","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Mean Weekly Frequency of Urinary Incontinence Episodes at Week 12","description":"Reduction in number of incontinent episodes, evaluated as mITT (modified intention to treat), after 12 weeks of treatment compared to baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.8","spread":"28.7"},{"groupId":"OG001","value":"-21.9","spread":"25.1"},{"groupId":"OG002","value":"-20.0","spread":"27.0"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":210},"commonTop":["Dry mouth","Upper respiratory tract infection","Headache","Urinary tract infection","Application site erythema"]}}}